Zafgen (ZFGN) Misses Q2 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/7/2026

1. MRVL
2. ZS
3. PENG
4. STZ
5. NVDA
6. MSFT
7. SPY
8. SKYD
9. CRWV
10. CRBU

Go back to Zafgen (ZFGN) Misses Q2 EPS by 4c

Zafgen Reports Second Quarter 2017 Financial Results

August 8, 2017 4:06 PM EDT

-ZGN-1061 Phase 1 Data Support Continued Development for Obese Patients with Type 2 Diabetes-

-Company to Initiate Phase 2 Clinical Trial in Third Quarter of This Year-

-Ends Quarter with Cash, Cash Equivalents and Marketable Securities of $106 Million; Increases Year-End Cash Guidance to Greater than $70 Million-

BOSTON, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq: ZFGN), today announced its second quarter 2017 financial results.

In the second quarter, we reached a critical milestone in the development program for ZGN-1061,... More